Jazz Pharmaceuticals shared a post on LinkedIn:
“Increased understanding around HER2 biology is helping to shape the future of cancer care. Amal Melhem-Bertrandt, Vice President and Oncology Therapy Area Head, R&D, discusses the importance of leveraging biomarker strategies for developing therapies that can effectively target HER2-expressing cancers.
As science continues to evolve, biomarker strategies remain central to identifying new opportunities to advance #oncology treatment and improve outcomes for people living with these challenging cancers.”
Other articles about Jazz Pharmaceuticals on OncoDaily.